【摘要】

目的 本研究探讨安非他酮对精神分裂症患者认知功能的干预效果。
方法 以某精神病医院住院精神分裂症患者80例为研究对象，研究组在原有利培酮剂量不变的基础上，联用安非他酮 150mg/d，对照组原有利培酮剂量不变。两组患者分别于治疗前、治疗后8周后分别接受量表评估。采用中文版认知功能成套测验工具（MCCB）评定对认知功能的临床疗效；采用阳性与阴性症状量表（PANSS）评定治疗前后患者精神病性症状的变化；以副反应反应量表（TESS）及化验和辅助检查进行安全性评估。
结果 研究组治疗8周末认知功能测验成绩与入组时相比，处理速度、视觉学习和记忆、工作记忆、注意、推理与问题解决测验成绩差异均有统计学意义（P＜0.05）；PANSS总分及阴性症状分量表分差异有统计学意义（P＜0.05）。组间比较以上评估差异有统计学意义（P＜0.05），研究组优于对照组。
结论 利培酮联合低剂量安非他酮可以改善精神分裂症患者的认知功能。

【Abstract】

Objective The research is to explore the effect of bupropion on cognitive function in patients with schizophrenia. Method We selected 80 cases of hospitalized patients with schizophrenia who are use risperidone only from A mental hospital，Patients were randomly divided into the Study Group and the Control Group , the study group added bupropion (150 mg, qd), the control group added placebo instead . The two groups were evaluated before and after 8 weeks of treatment respectively. MATRICS consensus cognitive battery(MCCB) was used to evaluate the cognitive function of the patients.The positive and negative symptom scale (PANSS) was used to evaluate the changes of psychotic symptoms before and after treatment. The side effects scale (TESS) and laboratory tests and auxiliary examinations were used for safety assessment. Result Study group :After 8 weeks of treatment, cognitive function test scores compared with baseline, there were significant improvement in the processing speed, visual learning and memory, working memory, attention and NBA-maze(P<0.05) . There was a significant change in the total score of PANSS and the scale of negative symptoms (P<0.05) . The study group was better than the control group .
Conclusion   Low-dose bupropion combined with risperidone may improve the cognition function of patients with schizophrenia .